Payment overview · 2025
General Payments
$1,003.22
21 reported records · 12 companies
Healthcare provider profile · identity verified
Randy Robert Heisser, MD
Allopathic & Osteopathic Physicians|Family Medicine · EAST RIDGE, TN · NPI 1689620999
Verified facts
What the public records show
CMS Open Payments records show Randy Robert Heisser, MD received $1,003.22 in general payments during 2025 across 21 reported records.
Kerecis Limited accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kerecis Limited | Unresolved — no canonical attribution shown | $269.19 | 26.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.89 | 19.0% | 2 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $125.31 | 12.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $110.18 | 11.0% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $89.40 | 8.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.86 | 6.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $59.40 | 5.9% | 3 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $31.53 | 3.1% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $19.12 | 1.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.73 | 1.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.51 | 1.4% | 1 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $14.10 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,003.22 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $269.19 | 4 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $269.19 | 4 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $125.31 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $110.18 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $109.86 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $89.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $81.03 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $63.86 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $59.40 | 3 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $31.53 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| COOK CELECT Normalized: cook celect |
Device | Cook Medical LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 913 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 674 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 409 | 79 |
| Potassium Chloride | Potassium Chloride | 282 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 278 | 65 |
| Quetiapine Fumarate | Quetiapine Fumarate | 274 | 50 |
| Carvedilol | Carvedilol | 262 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 73 |
| Furosemide | Furosemide | 258 | 57 |
| Lisinopril | Lisinopril | 227 | 43 |
| Omeprazole | Omeprazole | 223 | 44 |
| Lactulose | Lactulose | 214 | 19 |
| Sertraline Hcl | Sertraline Hcl | 212 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 43 |
| Trazodone Hcl | Trazodone Hcl | 206 | 45 |
| Losartan Potassium | Losartan Potassium | 188 | 44 |
| Metformin Hcl | Metformin Hcl | 177 | 37 |
| Donepezil Hcl | Donepezil Hcl | 172 | 30 |
| Xarelto | Rivaroxaban | 171 | 13 |
| Mirtazapine | Mirtazapine | 161 | 36 |
| Levetiracetam | Levetiracetam | 154 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 124 | 31 |
| Divalproex Sodium | Divalproex Sodium | 113 | 21 |
| Spironolactone | Spironolactone | 108 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 35 |
| Latanoprost | Latanoprost | 102 | 15 |
| Famotidine | Famotidine | 100 | 27 |
| Montelukast Sodium | Montelukast Sodium | 99 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 88 | 41 |
| Risperidone | Risperidone | 88 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 12 |
| Baclofen | Baclofen | 79 | suppressed |
| Memantine Hcl | Memantine Hcl | 73 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 72 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 12 |
| Buspirone Hcl | Buspirone Hcl | 67 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | suppressed |
| Simvastatin | Simvastatin | 67 | 15 |
| Allopurinol | Allopurinol | 64 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 18 |
| Farxiga | Dapagliflozin Propanediol | 64 | suppressed |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Bumetanide | Bumetanide | 57 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 53 | 35 |
| Bupropion Xl | Bupropion Hcl | 51 | suppressed |
| Xifaxan | Rifaximin | 50 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 32 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 46 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Finasteride | Finasteride | 41 | 11 |
| Sucralfate | Sucralfate | 41 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 11 |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | suppressed |
| Gabapentin | Gabapentin | 24 | 17 |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Nystatin | Nystatin | 22 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 16 |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 17 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Atenolol | Atenolol | 15 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 14 |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,003.22 · 21 records | Kerecis Limited | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, COOK CELECT, INGREZZA, Kerecis GraftGuide, Kerecis SurgiClose, Ohtuvayre, REXULTI, TARPEYO, Zunveyl | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error